Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from EZZ Life Science Holdings Ltd. ( (AU:EZZ) ) is now available.
EZZ Life Science reported Q3 FY26 customer receipts of $8.85 million, a 25% decline amid softer demand on major e-commerce platforms, leading to a net operating cash outflow of $3.2 million. The company ended the quarter with $9.96 million in cash and no debt, while investing in inventory, marketing and strategic initiatives to support longer-term growth.
To strengthen distribution and market reach, EZZ signed a four-year exclusive global distribution deal with Aumake, featuring $10 million in minimum purchase commitments, and entered a strategic cooperation with JD Health to bolster omni-channel execution in China. It also upgraded key products, launched the MeTime Series and a tailored children’s product, expanded pharmacy distribution in Australia, intensified brand-building activities internationally, and reinforced its governance structure with new board appointments.
More about EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited is an Australia-based life science company focused on consumer health products. It develops and distributes high-quality supplements and wellness formulations through omnichannel models across Australia, New Zealand, China, the United States and other global markets, targeting premium, brand-led segments in competitive e-commerce and retail channels.
Average Trading Volume: 23,768
Technical Sentiment Signal: Sell
Current Market Cap: A$34.81M
For an in-depth examination of EZZ stock, go to TipRanks’ Overview page.